Wrembel-Wargocka J, Jabłońska H, Chomiczewski K
Zakładu Radiobiologii Wojskowego Instytutu Higieny i Epidemiologii.
Przegl Lek. 1996;53(11):820-5.
High doses of chemo- and radiotherapy, while theoretically more effective, are accompanied by severe toxicities and normal cells damage. This may have important implications for patients' management and can result in significant morbidity. Therefore, it is imperative to protect normal tissues from both the early and late damage caused by high doses of radiation and chemotherapy. Among the radioprotective agents synthetized during the last 30 years. Amifostine appeared to be one of the most promising. It was shown that this compound can protect normal cells from the toxic effects of ionizing radiation and chemotheraphy without affecting the efficacy of the therapy. Since 1986, initial trials with Amifostine in patients with diverse advanced neoplasms treated by chemotherapy and radiation therapy have been performed. Published data suggest that pretreatment with Amifostine significantly decreases hematologic, mucosal and renal toxicity as well as the frequency of neuropathy. Also, significant reduction in the frequency of hospitalization, mean hospital stay, and the number of days on antibiotics was observed after application of Amifostine.
高剂量的化疗和放疗虽然理论上更有效，但会伴随着严重的毒性和正常细胞损伤。这可能对患者的治疗产生重要影响，并可能导致显著的发病率。因此，保护正常组织免受高剂量放疗和化疗引起的早期和晚期损伤至关重要。在过去30年合成的辐射防护剂中，氨磷汀似乎是最有前景的之一。研究表明，这种化合物可以保护正常细胞免受电离辐射和化疗的毒性作用，而不影响治疗效果。自1986年以来，已经对接受化疗和放疗的各种晚期肿瘤患者进行了氨磷汀的初步试验。已发表的数据表明，氨磷汀预处理可显著降低血液学、黏膜和肾脏毒性以及神经病变的发生率。此外，应用氨磷汀后，住院频率、平均住院时间和使用抗生素的天数均显著减少。
